APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis C Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis C Drug Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchHepatitis C Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis C Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hepatitis C Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis C Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis C Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Hepatitis C Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatitis C Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatitis C Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis C Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatitis C Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatitis C Drug market include Johnson & Johnson, Merck, AbbVie, Kenilworth, Gilead and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatitis C Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis C Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis C Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis C Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis C Drug Segment by Company

Johnson & Johnson

Merck

AbbVie

Kenilworth

Gilead

Bristol-Myers Squibb

Hepatitis C Drug Segment by Type

Rx

OTC

Hepatitis C Drug Segment by Application

Hospital

Clinic

Other

Hepatitis C Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatitis C Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis C Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis C Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis C Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis C Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis C Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis C Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis C Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis C Drug industry.

Chapter 3: Detailed analysis of Hepatitis C Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis C Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis C Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis C Drug Industry Trends Table 2. Hepatitis C Drug Industry Drivers Table 3. Hepatitis C Drug Industry Opportunities and Challenges Table 4. Hepatitis C Drug Industry Restraints Table 5. Global Hepatitis C Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis C Drug Revenue Share by Company (2021-2026) Table 7. Global Hepatitis C Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Hepatitis C Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis C Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hepatitis C Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis C Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis C Drug Company, Product Type & Application Table 13. Global Hepatitis C Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis C Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rx Table 18. Significant Companies of OTC Table 19. Global Hepatitis C Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Hepatitis C Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Hepatitis C Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Hepatitis C Drug Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis C Drug Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis C Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis C Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis C Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis C Drug Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis C Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Hepatitis C Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Hepatitis C Drug Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Hepatitis C Drug Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Hepatitis C Drug Sales Volume Share by Application (2021-2026) Table 36. Global Hepatitis C Drug Sales Volume Share by Application (2027-2032) Table 37. Global Hepatitis C Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hepatitis C Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hepatitis C Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hepatitis C Drug Sales Value Share by Application (2021-2026) Table 41. Global Hepatitis C Drug Sales Value Share by Application (2027-2032) Table 42. Global Hepatitis C Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Hepatitis C Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Hepatitis C Drug Sales Market Share by Region (2021-2026) Table 45. Global Hepatitis C Drug Sales by Region (2027-2032) & (K Units) Table 46. Global Hepatitis C Drug Sales Market Share by Region (2027-2032) Table 47. Global Hepatitis C Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hepatitis C Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hepatitis C Drug Sales Value Share by Region (2021-2026) Table 50. Global Hepatitis C Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hepatitis C Drug Sales Value Share by Region (2027-2032) Table 52. Global Hepatitis C Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Hepatitis C Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Hepatitis C Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Hepatitis C Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hepatitis C Drug Sales by Country (2021-2026) & (K Units) Table 57. Global Hepatitis C Drug Sales Market Share by Country (2021-2026) Table 58. Global Hepatitis C Drug Sales by Country (2027-2032) & (K Units) Table 59. Global Hepatitis C Drug Sales Market Share by Country (2027-2032) Table 60. Global Hepatitis C Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hepatitis C Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Hepatitis C Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hepatitis C Drug Sales Value Market Share by Country (2027-2032) Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Hepatitis C Drug Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Merck Hepatitis C Drug Product Portfolio Table 73. Merck Recent Development Table 74. AbbVie Company Information Table 75. AbbVie Business Overview Table 76. AbbVie Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. AbbVie Hepatitis C Drug Product Portfolio Table 78. AbbVie Recent Development Table 79. Kenilworth Company Information Table 80. Kenilworth Business Overview Table 81. Kenilworth Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Kenilworth Hepatitis C Drug Product Portfolio Table 83. Kenilworth Recent Development Table 84. Gilead Company Information Table 85. Gilead Business Overview Table 86. Gilead Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead Hepatitis C Drug Product Portfolio Table 88. Gilead Recent Development Table 89. Bristol-Myers Squibb Company Information Table 90. Bristol-Myers Squibb Business Overview Table 91. Bristol-Myers Squibb Hepatitis C Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Bristol-Myers Squibb Hepatitis C Drug Product Portfolio Table 93. Bristol-Myers Squibb Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Hepatitis C Drug Distributors List Table 97. Hepatitis C Drug Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Hepatitis C Drug Product Image Figure 2. Global Hepatitis C Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis C Drug Sales (2021-2032) & (K Units) Figure 5. Global Hepatitis C Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hepatitis C Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rx Image Figure 10. OTC Image Figure 11. Global Hepatitis C Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Hepatitis C Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis C Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis C Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis C Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis C Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Hepatitis C Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Hepatitis C Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatitis C Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Hepatitis C Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hepatitis C Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatitis C Drug Sales Value Share by Application (2021-2032) Figure 26. Global Hepatitis C Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Hepatitis C Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hepatitis C Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hepatitis C Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hepatitis C Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hepatitis C Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hepatitis C Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hepatitis C Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hepatitis C Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hepatitis C Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hepatitis C Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hepatitis C Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hepatitis C Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Johnson & Johnson
  • Merck
  • AbbVie
  • Kenilworth
  • Gilead
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis C Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis C Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis C Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis C Drug Market Dynamics
  1. 2.1 Hepatitis C Drug Industry Trends
  2. 2.2 Hepatitis C Drug Industry Drivers
  3. 2.3 Hepatitis C Drug Industry Opportunities and Challenges
  4. 2.4 Hepatitis C Drug Industry Restraints
3 Hepatitis C Drug Market by Company
  1. 3.1 Global Hepatitis C Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis C Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis C Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis C Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis C Drug Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis C Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis C Drug Company Product Type and Application
  8. 3.8 Global Hepatitis C Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis C Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis C Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis C Drug Market by Type
  1. 4.1 Hepatitis C Drug Type Introduction
  2. 4.1.1 Rx
  3. 4.1.2 OTC
  4. 4.2 Global Hepatitis C Drug Sales Volume by Type
  5. 4.2.1 Global Hepatitis C Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis C Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis C Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis C Drug Sales Value by Type
  9. 4.3.1 Global Hepatitis C Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis C Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis C Drug Sales Value Share by Type (2021-2032)
5 Hepatitis C Drug Market by Application
  1. 5.1 Hepatitis C Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Hepatitis C Drug Sales Volume by Application
  6. 5.2.1 Global Hepatitis C Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatitis C Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hepatitis C Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hepatitis C Drug Sales Value by Application
  10. 5.3.1 Global Hepatitis C Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatitis C Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hepatitis C Drug Sales Value Share by Application (2021-2032)
6 Hepatitis C Drug Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis C Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis C Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis C Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis C Drug Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis C Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis C Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis C Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis C Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis C Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis C Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis C Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis C Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis C Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis C Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis C Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis C Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis C Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis C Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis C Drug Sales Value Share by Country, 2025 VS 2032
7 Hepatitis C Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis C Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis C Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis C Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis C Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis C Drug Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis C Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis C Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis C Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis C Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis C Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis C Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Hepatitis C Drug Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Hepatitis C Drug Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Hepatitis C Drug Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 Kenilworth
  20. 8.4.1 Kenilworth Company Information
  21. 8.4.2 Kenilworth Business Overview
  22. 8.4.3 Kenilworth Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kenilworth Hepatitis C Drug Product Portfolio
  24. 8.4.5 Kenilworth Recent Developments
  25. 8.5 Gilead
  26. 8.5.1 Gilead Company Information
  27. 8.5.2 Gilead Business Overview
  28. 8.5.3 Gilead Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Hepatitis C Drug Product Portfolio
  30. 8.5.5 Gilead Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Hepatitis C Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Hepatitis C Drug Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis C Drug Value Chain Analysis
  2. 9.1.1 Hepatitis C Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis C Drug Sales Mode & Process
  6. 9.2 Hepatitis C Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis C Drug Distributors
  9. 9.2.3 Hepatitis C Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst